Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
New commercial opportunity for PBT2
MELBOURNE, Australia, Dec. 22, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat...
Read more: Alterity and UniQuest partner to reverse bacterial resistance to antibiotics